Related Experiment Video

Updated: Jun 28, 2026

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells
06:29

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells

Published on: July 30, 2020

Update on aurora kinase inhibitors in gynecologic malignancies

Xia Tao1, Hye S Chon, Siqing Fu

  • 1Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

Recent Patents on Anti-Cancer Drug Discovery
|November 11, 2008
PubMed

Insights

Aurora kinases are crucial for cell division and cancer growth. This review covers new patented inhibitors targeting these kinases for gynecologic tumors, showing promise in preclinical and clinical studies.

Area of Science:

  • Molecular Biology
  • Oncology
  • Pharmacology

Background:

  • Aurora kinases (A and B) are vital for mitosis, chromosome segregation, and cytokinesis.
  • Overexpression of Aurora kinases A and B is linked to poor prognosis in gynecologic cancers.
  • Targeting Aurora kinases is a promising therapeutic strategy for cancer treatment.

Purpose of the Study:

  • To review recent advances in patented Aurora kinase inhibitors for gynecologic tumors.
  • To summarize findings from preclinical studies and clinical trials.
  • To highlight the therapeutic potential of these inhibitors.

Main Methods:

  • Literature review of preclinical studies.
  • Analysis of clinical trial data.
  • Focus on patented Aurora kinase inhibitors.

Main Results:

  • Over 30 Aurora kinase inhibitors have been developed.
  • Some inhibitors demonstrate efficacy in targeted cancer therapies.
  • Ongoing investigations into the therapeutic potential of various inhibitors.

Conclusions:

  • Aurora kinase inhibitors represent a significant area of pharmaceutical development for gynecologic cancers.
  • Targeted inhibition shows promise for improving patient outcomes.
  • Further clinical investigation is warranted to establish efficacy and safety.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...